ELFABRIO DIN 02563568
Status: Marketed
Holder: CHIESI FARMACEUTICI S.P.A.
Health Canada record
| Active ingredient(s) | PEGUNIGALSIDASE ALFA 5 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | A16AB20 PEGUNIGALSIDASE ALFA |
|---|
| Original market date | 12-May-2026 |
|---|
| Current status date | 12-May-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Chiesi Farmaceutici S.p.A. — licence , not currently licensed, last inspection rating C (2023-09-29).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PEGUNIGALSIDASE ALFA
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02563576 | ELFABRIO | CHIESI FARMACEUTICI S.P.A. | Solution | PEGUNIGALSIDASE ALFA 20 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 36501 | 2025-12-09 | New Drug Submission (NDS) | |
Request a quote for ELFABRIO
How to read a Canadian DIN record